Slide 7 in the latest presentation states this about AGC's aspirations:
"Ambition and resources dedicated to supply global market"
I think if the STEP trial results are positive, AGC will want to lock in Progenza and take it global for OA and other inflammatory areas. More $$ for RGS then, upfront licensing and royalty streams etc. for each market, would it be a global deal?